131 related articles for article (PubMed ID: 11165756)
1. Clinical value of the wild-type estrogen receptor beta expression in breast cancer.
Omoto Y; Inoue S; Ogawa S; Toyama T; Yamashita H; Muramatsu M; Kobayashi S; Iwase H
Cancer Lett; 2001 Feb; 163(2):207-12. PubMed ID: 11165756
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.
Järvinen TA; Pelto-Huikko M; Holli K; Isola J
Am J Pathol; 2000 Jan; 156(1):29-35. PubMed ID: 10623650
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
Demir H; Turna H; Can G; Ilvan S
J BUON; 2010; 15(4):774-82. PubMed ID: 21229645
[TBL] [Abstract][Full Text] [Related]
4. Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain.
AlZaman AS; Mughal SA; AlZaman YS; AlZaman ES
Saudi Med J; 2016 Jan; 37(1):37-42. PubMed ID: 26739972
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
6. Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression.
Umekita Y; Souda M; Ohi Y; Sagara Y; Rai Y; Takahama T; Yoshida H
Pathol Int; 2006 Aug; 56(8):423-7. PubMed ID: 16872435
[TBL] [Abstract][Full Text] [Related]
7. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
8. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas.
Shaw JA; Udokang K; Mosquera JM; Chauhan H; Jones JL; Walker RA
J Pathol; 2002 Dec; 198(4):450-7. PubMed ID: 12434414
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.
Sofi GN; Sofi JN; Nadeem R; Shiekh RY; Khan FA; Sofi AA; Bhat HA; Bhat RA
Asian Pac J Cancer Prev; 2012; 13(10):5047-52. PubMed ID: 23244108
[TBL] [Abstract][Full Text] [Related]
11. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
[TBL] [Abstract][Full Text] [Related]
14. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer.
Huang B; Omoto Y; Iwase H; Yamashita H; Toyama T; Coombes RC; Filipovic A; Warner M; Gustafsson JÅ
Proc Natl Acad Sci U S A; 2014 Feb; 111(5):1933-8. PubMed ID: 24449868
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
[TBL] [Abstract][Full Text] [Related]
17. Investigation of immunohistochemical ERα, ERβ and ERβcx expressions in normal and neoplastic breast tissues.
Bozkurt KK; Kapucuoğlu N
Pathol Res Pract; 2012 Mar; 208(3):133-9. PubMed ID: 22336175
[TBL] [Abstract][Full Text] [Related]
18. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
19. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
[TBL] [Abstract][Full Text] [Related]
20. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Ito Y; Akiyama F
Breast; 2014 Dec; 23(6):754-62. PubMed ID: 25176593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]